Home/Exo Therapeutics/Alan Saghatelian, PhD

AS

Alan Saghatelian, PhD

Co-Founder

Exo Therapeutics

Therapeutic Areas

Oncology Inflammation

Exo Therapeutics Pipeline

Drug	Indication	Phase
EXO-TBKi	Inflammatory diseases (via STING pathway/TBK1 inhibition)	Pre-clinical

Leadership Team at Exo Therapeutics

Ronenn Roubenoff, MD

Senior Clinical Advisor

Dave Guerin, Ph.D.

Senior Medicinal Chemistry Advisor

Kevin Leach, Ph.D., DABT

Senior Drug Development Advisor

View full Exo Therapeutics profile